Plasticell signs stem cell research collaborations with Singapore academia
Posted: 31 March 2017 | Niamh Marriott (Drug Target Review) | No comments yet
Plasticell, a developer of stem cell technologies and cell-based therapies, has signed agreements with the Agency for Science, Technology and Research (A*STAR) and the Nanyang Technological University (NTU) to progress its therapeutic stem cell pipeline.
“We are delighted to have put together this collaboration which has such enormous potential for the creation of next-generation stem cell products,” commented Dr Yen Choo, founder and Executive Chairman of Plasticell.
Separate agreements with the two Singapore research centres encompass technology licensing, collaborative research and scientific exchange visits.
Plasticell will initially collaborate with the laboratories of Professor Peter Dröge (School of Biological Sciences, NTU) and Dr Farid Ghadessy (p53Lab, A*STAR) to apply proprietary genome editing technology to insert functional multi-transgene cassettes into specific loci of human stem cell lines.
The engineered lines will be used by Plasticell in multiple projects focused on precisely directed stem cell differentiation, phenotypic screening for drug discovery and in next-generation immuno-oncology applications.
Drug Target Review has just announced the launch of its NEW and EXCLUSIVE report examining the evolution of AI and informatics in drug discovery and development.
In this 63 page in-depth report, experts and researchers explore the key benefits of AI and informatics processes, reveal where the challenges lie for the implementation of AI and how they see the use of these technologies streamlining workflows in the future.
Also featured are exclusive interviews with leading scientists from AstraZeneca, Auransa, PolarisQB and Chalmers University of Technology.
About Plasticell
Plasticell is a biotechnology company leading the use of high throughput technologies to develop stem cell therapies. The Company’s therapeutic focus is in hematopoietic stem cell therapy, anaemia and thrombocytopenia, cancer immunotherapy and diabetes/obesity.
Plasticell’s Combinatorial Cell Culture (CombiCult) platform technology, allows it to test very large numbers of cell culture variables in combinations to discover optimal laboratory protocols for the manipulation of stem cells and other cell cultures and has received a number of industry awards including the Queen’s Award for Enterprise in Innovation and the R&D 100 Award.
Related topics
Immunooncology, Immunotherapy, Stem Cells, Therapeutics
Related organisations
Agency for Science Technology and Research (A*STAR), Nanyang Technological University (NTU), Plasticell
Related people
Dr Farid Ghadessy, Dr Yen Choo, Professor Peter Dröge
